publication date: Nov. 9, 2018

Drugs & Targets FDA approves Empliciti + pomalidomide and dexamethasone for multiple myeloma

FDA has approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.

Empliciti is sponsored by Bristol-Myers Squibb Co.

In ELOQUENT-3, a randomized, open-label, phase II trial, EPd demonstrated benefit in patients with relapsed or refractory multiple myeloma, doubling both median progression-free survival and overall response rate versus pomalidomide and dexamethasone.

Empliciti with pomalidomide and dexamethasone is associated with Warnings and Precautions related to: infusion reactions, infections, secondary primary malignancies, hepatotoxicity, interference with determination of complete response, pregnancy/females and males of reproductive potential and adverse reactions.

Following priority review by the FDA, EPd is the first triplet combination to be approved based on a randomized clinical trial using Pd as a comparator.

Results from the trial include:

Progression-free survival (primary endpoint, investigator-assessed): EPd reduced the risk of disease progression by 46% (hazard ratio: 0.54; 95% confidence interval: 0.34 to 0.86, p=0.0078), demonstrating a median PFS of 10.25 months (95% CI: 5.59 to non-estimable) vs. 4.67 months (95% CI: 2.83 to 7.16) for Pd alone after a minimum follow-up of 9.1 months.

Overall response … Continue reading FDA approves Empliciti + pomalidomide and dexamethasone for multiple myeloma

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.